Peptide PHSCNK as an integrin α5β1 antagonist targets stealth liposomes to integrin-overexpressing melanoma

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 7, 2012, Pages 1152-1161

  Dai, Wenbing ^a   Yang, Tingyuan ^a   Wang, Yiguang ^a   Wang, Xueqing ^a   Wang, Jiancheng ^a   Zhang, Xuan ^a   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Doxorubicin; Integrins; Liposomes; PHSCNK; Targeted delivery system

Indexed keywords

ANTI-TUMOR ACTIVITIES; BIODISTRIBUTIONS; C57BL/6 MICE; CANCER THERAPY; CHITOSAN NANOPARTICLES; DELIVERY SYSTEMS; DELIVERY TARGETS; DOXORUBICIN; HEPATOCARCINOMA; HOMING PEPTIDE; IN-PHASE; INTEGRINS; INTRACELLULAR UPTAKE; PHSCNK; STEALTH LIPOSOMES; SURVIVAL TIME; TARGETED DELIVERY; TUMOR INHIBITION; TUMOR THERAPY;

AMIDES; AMINO ACIDS; DERMATOLOGY; NANOPARTICLES; ONCOLOGY; PEPTIDES; TUMORS;

LIPOSOMES;

DOXORUBICIN; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TARGETING; IC 50; MALE; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SURVIVAL TIME;

AMINO ACID SEQUENCE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DOXORUBICIN; DRUG DELIVERY SYSTEMS; INTEGRIN ALPHA5BETA1; LIPOSOMES; MELANOMA; MICE; MICE, INBRED C57BL; PEPTIDES; UP-REGULATION;

MURINAE; MUS;

EID: 84866496689     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.01.003     Document Type: Article

References (39)

1. Sulkowski W.W., Pentak D., Nowak K. The influence of temperature cholesterol content and pH on liposome stability. J Mol Struct 2005, 744:737-747.
2. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
3. Muggia F. Doxorubicin-polymer conjugates: further demonstration of the concept of enhanced permeability and retention. Clin Cancer Res 1999, 5:7-8.
4. Xiong X.B., Huang Y., Lu W.L., Zhang H., Zhang X., Zhang Q. Enhanced intracellular uptake of sterically stabilized liposomal doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res 2005, 22:933-939.
5. Sapra P., Tyagi P., Allen T.M. Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2005, 2:369-381.
6. Garde S.V., Forte A.J., Ge M., Lepekhin E.A., Panchal C.J., Rabbani S.A., et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anti-Cancer Drug 2007, 18:1189-1200.
7. Maeda N., Takeuchi Y., Takada M., Sadzuka Y., Namba Y., Oku N. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulation liposome. J Control Release 2004, 100:41-52.
8. Schiffelers R.M., Koning G.A., Hagen T.L., Fens M.H., Schraa A.J., Janssen A.P., et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 2003, 91:115-122.
9. Zhao H., Wang J.C., Sun Q.S., Luo C.L., Zhang Q. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target 2009, 17:10-18.
10. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Nagai T., et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 2005, 107:262-275.
11. Xiong X.B., Huang Y., Lu W.L., Zhang X., Zhang H., Nagai T., et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci 2005, 94:1782-1793.
12. Singh S.R., Grossniklaus H.E., Kang S.J., Edelhauser H.F., Ambati B.K., Kompella U.B. Intravenous transferrin, RGD peptide and dual-targeted nanoparticles enhance anti-VEGF intraceptor gene delivery to laser-induced CNV. Gene Ther 2009, 16:645-659.
13. Dijkgraaf I., Rijnders A.Y., Soede A., Dechesne A.C., Esse G.V., Brouwer A.J., et al. Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1, 3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org Biomol Chem 2007, 5:935-944.
14. Wang Y.G., Wang X., Zhang Y.F., Yang S.J., Wang J.C., Zhang X., et al. RGD-modified polymeric micelles as potential carriers for targeted delivery to integrin-overexpressing tumor vasculature and tumor cells. J Drug Target 2009, 7:459-467.
15. Wang X., Wang Y.G., Chen X.M., Wang J.C., Zhang X., Zhang Q. NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. J Control Release 2009, 39:56-62.
16. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69:11-25.
17. Varne J.A., Cheresh D.A., Cheresh D.A. Integrins and cancer. Curr Opin Cell Biol 1997, 8:724-730.
18. Jere E., Meredith J., Martin A.S. Integrins, adhesion and apoptosis. Trends Cell Biol 1997, 7:146-150.
19. Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat Rev Cancer 2001, 2:91-100.
20. Serini G., Valdembri D., Bussolino F. Integrins and angiogenesis: a sticky business. Exp Cell Res 2006, 312:651-658.
21. Livant D.L., Brabec R.K., Pienta K.J., Allen D.L., Kurachi K., Markwart S., et al. Anti-invasive, anti-tumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 2000, 60:309-320.
22. Plunkett M.L., Beck I., Avery J. Combining low dose chemotherapy with low dose anti-angiogenic agents (ATN-161 and ATN-224) leads to increased anti-tumor activity in prostate cancer xenograft models. Proc Am Assoc Cancer Res 2003, 44:3730.
23. Khalili P., Arakelian A., Chen G. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol Cancer Ther 2006, 5:2271-2280.
24. Donate F., Parry G.C., Shaked Y., Hensley H., Guan X.J., Beck I., et al. Pharmacology of the novel antiangiogenic PeptideATN-161(Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clin Cancer Res 2008, 14:2317-2324.
25. Dai W.B., Yang T.Y., Wang X.Q., Wang J.C., Zhang X., Zhang Q. PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells. J Drug Target 2010, 18:254-263.
26. Ravandi A., Kuksis A., Shaikh A., Jackowski G. Preparation of Schiff base adducts of phosphatidylcholine core aldehydes and aminophospholipids, amino acids, and myoglobin. Lipids 1997, 32:989-1001.
27. Crack J.C., Green J., Le Brun N.E., Thomson A.J. Detection of Sulfide Release from the Oxygen-sensing [4Fe-4S] Cluster of FNR. J Biol Chem 2006, 281:18909-18913.
28. Charrois G.J., Allen T.M. Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. Biochim Biophys Acta 2004, 1663:167-177.
29. Shmeeda H., Amitay Y., Gorin J., Dina T., Mak L., Ogorka J., et al. Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. J Control Release 2010, 146:76-83.
30. Maeda N., Takeuchi Y., Takada M., Sadzuka Y., Namba Y., Oku N. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J Control Release 2004, 100:41-54.
31. Xiang Y., Liang L., Wang X.Q., Wang J.C., Zhang X., Zhang Q. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicin-loaded liposomes. J Control Release 2011, 152:402-410.
32. Sun M.J., Wang Y., Shen J., Xiao Y.Y., Su Z.G., Ping Q.N. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo. Nanotechnology 2010, 21:475101.
33. Emanuel N., Kedar E., Bolotin E., Smorodinsky N.I., Barenholz Y. Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice. Pharm Res 1996, 13:861-868.
34. Turka M.J., Watersb D.J., Low P.S. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett 2004, 213:165-172.
35. Linuma H., Maruyama K., Okinaga K. Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposomes on peritoneal dissemination of gastric cancer. Int J Cancer 2002, 299:130-137.
36. Sakakibara T., Chen F.A., Kida H., Kunieda R.E., Cuenca F.J., Martin R.B. Doxorubicin encapsulated in sterically stabilized liposomes is superior to free drug or drug-containing conventional liposomes at suppressing growth and metastases of human lung tumor xenografts. Cancer Res 1996, 56:3743-3746.
37. Lasic D.D. Doxorubicin in sterically stabilized liposomes. Nature 1996, 380:561-562.
38. Tardi P.G., Boman N.L., Cullis P.R. Liposomal doxorubicin. J Drug Target 1996, 4:129-141.
39. Safra T. Cardiac safety of liposomal anthracyclines. Oncocogist 2003, 8:17-24.